SCHEMBL711338

SCHEMBL711338

O=C(O)c1cc(OCc2ccccc2)ccc1NS(=O)(=O)c1cccs1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.63
BCL2A1 Q16548 2/20 0.63
HTT P42858 1/20 0.52
PTGER3 P43115 2/20 0.51
PTGER1 P34995 1/20 0.51
PTGER4 P35408 1/20 0.51
PTGER2 P43116 1/20 0.51
CTSV O60911 3/20 0.47
CTSL P07711 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
PKM P14618 1/20 0.47
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
BRAF P15056 1/20 0.46
HKDC1 Q2TB90 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
NPC1 O15118 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713051 0.91 ALDH1A1 (0.54) MCL1BCL2A1HTTPTGER3PTGER1
SCHEMBL22213615 0.79 MCL1 (0.64) MCL1BCL2A1MEN1KMT2APKM
SCHEMBL3978628 0.78 METAP2 (0.67) MCL1BCL2A1HTTMEN1KMT2A
SCHEMBL18152031 0.77 MCL1 (1.00) MCL1BCL2A1
SCHEMBL9931423 0.77 CCR2 (0.64) MEN1KMT2APKM
SCHEMBL28134461 0.77 MCL1 (0.56) MCL1BCL2A1CTSVCTSLMEN1
SCHEMBL22762358 0.76 MCL1 (0.54) MCL1BCL2A1CTSVCTSLMEN1
SCHEMBL22762666 0.74 MCL1 (0.60) MCL1BCL2A1MEN1KMT2APKM
SCHEMBL22762667 0.74 KDM4E (0.60) MCL1CTSVCTSLMEN1KMT2A
SCHEMBL25140636 0.74 SMN1; SMN2 (0.70) MCL1BCL2A1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK MCL1 4054/4885BCL2A1 4591/4885HTT 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.